Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Adjuvant Docetaxel-based Chemotherapy in Resected Stage IB-II NSCLC
2005-004029-24Phase 2Completed
- Sponsor
- Thoracale Oncologie Groep Antwerpen
- Start
- May 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel in non-small cell lung cancer (NSCLC), sponsored by Thoracale Oncologie Groep Antwerpen. Primary endpoint: Success of delivery of treatment. Started May 2007; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004029-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004029-24.